Drugs / GSK2849330
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02345174 | Mar 2015 → Jun 2016 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01966445 | Nov 2013 → Sep 2017 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2849330 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01966445 ↗ |
| Modality | Monoclonal antibody | “Anti-Her3 Monoclonal Antibody GSK2849330” NCT01966445 ↗ |